Search Results

You are looking at 51 - 60 of 71 items for :

  • "chemotherapy administration" x
  • All content x
Clear All
Full access

Emily van Seventer, J. Peter Marquardt, Amelie S. Troschel, Till D. Best, Nora Horick, Chinenye Azoba, Richard Newcomb, Eric J. Roeland, Michael Rosenthal, Christopher P. Bridge, Joseph A. Greer, Areej El-Jawahri, Jennifer Temel, Florian J. Fintelmann, and Ryan D. Nipp

chemotherapy administration/desensitization and scheduled procedures. We limited the current analysis to participants with a routine CT scan obtained within 45 days before study enrollment that imaged muscle at the level of the third lumbar vertebral body (L3

Full access

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

2007 showed that only 34% of these patients receive any chemotherapy, and that the rates decline as age increases. 3 A SEER database analysis of patients aged ≥66 years from 1992 through 2002 also demonstrated low rates of chemotherapy administration

Full access

Kelly G. Paulson and Shailender Bhatia

grade 4 events were reported. Based on the impressive results from this study, avelumab received approval by the FDA, Swissmedic, and the European Medical Association in 2017 for treatment of metastatic MCC, regardless of prior chemotherapy

Full access

A. Dimitrios Colevas, Sue S. Yom, David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, David W. Eisele, Moon Fenton, Robert L. Foote, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Matthew Witek, Frank Worden, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

chemotherapy administration, given either before or after definitive CRT), unadjusted comparisons of induction versus adjuvant chemotherapy did not reach statistical significance, but select adjusted comparisons indicated some improvements in disease

Full access

Andrew H. Ko and Christopher H. Crane

first phase III trial to use a chemoradiation regimen that is currently accepted as standard practice, in terms of both radiation dosing schedule and concurrent chemotherapy administration. Two other large phase III trials from Europe also evaluated

Full access

Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt, and Michael Westmoreland

colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte . Leuk Lymphoma 1997 ; 25 : 289 – 300 . 6 Timmer-Bonte JN de Boo TM Smit HJ

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

patient to tolerate therapy. Finally, patient preferences regarding mode of chemotherapy administration, duration of therapy, and goals of care will impact choice of therapy and must be elicited before initiation of therapy. General Approach to

Full access

Elizabeth Danielson, Jessica DeMartino, and Jill A. Mullen

considering drug coverage policy, second only to whether the drug is FDA-approved. Another area receiving attention is the setting for chemotherapy administration. During the interviews, it was identified that in general, chemotherapy administered in the

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho

. Gisselbrecht C Haioun C Lepage E . Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

GOG-0252 contained bevacizumab, which may have compensated for the effect of intraperitoneal chemotherapy administration. Number of Chemotherapy Cycles Before and After IDS As shown in supplemental eTable 2 , results from the PRIMOVAR-1 phase II